share_log

6-K: Novartis Second Quarter and Half Year 2024 Condensed Interim Financial Report – Supplementary Data

6-K: Novartis Second Quarter and Half Year 2024 Condensed Interim Financial Report – Supplementary Data

6-K:諾華製藥2024年第二季度和半年簡明中期財務報告—補充數據
美股SEC公告 ·  2024/07/18 18:11

Moomoo AI 已提取核心訊息

Novartis AG has submitted its Q2 2024 Financial Report to the U.S. Securities and Exchange Commission (SEC) on July 18, 2024. The filing includes the quarterly financial report and interactive data in XBRL format.The submission was officially signed by Paul Penepent, Head of Financial Reporting and Accounting, in compliance with the Securities Exchange Act of 1934 requirements. The company continues to file its annual reports under Form 20-F as a foreign private issuer.
Novartis AG has submitted its Q2 2024 Financial Report to the U.S. Securities and Exchange Commission (SEC) on July 18, 2024. The filing includes the quarterly financial report and interactive data in XBRL format.The submission was officially signed by Paul Penepent, Head of Financial Reporting and Accounting, in compliance with the Securities Exchange Act of 1934 requirements. The company continues to file its annual reports under Form 20-F as a foreign private issuer.
諾華製藥於2024年7月18日向美國證券交易委員會(SEC)提交了其2024年第二季度財務報告。此次提交包括季度財務報告和XBRL格式的互動數據。該提交由財務報告和會計負責人保羅·佩內潘特正式簽署,符合1934年證券交易法的要求。作爲外國私人發行人,該公司繼續根據20-F表格提交年度報告。
諾華製藥於2024年7月18日向美國證券交易委員會(SEC)提交了其2024年第二季度財務報告。此次提交包括季度財務報告和XBRL格式的互動數據。該提交由財務報告和會計負責人保羅·佩內潘特正式簽署,符合1934年證券交易法的要求。作爲外國私人發行人,該公司繼續根據20-F表格提交年度報告。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息